The Promise of viral phage therapy in hernia mesh infection, is this the biological 'silver bullet' of the future?
ANZ J Surg
.
2020 Nov;90(11):2161-2164.
doi: 10.1111/ans.16214.
Authors
Peter Speck
1
,
Morgyn Warner
2
,
Jason Clark
3
4
5
,
Anita Jacombs
6
,
Alex Karatassas
7
,
Chris Hensman
8
Affiliations
1
College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia.
2
Infectious Diseases Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
3
Microbiology and Infectious Diseases Directorate, SA Pathology, Adelaide, South Australia, Australia.
4
Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
5
Fixed Phage Ltd, Glasgow, UK.
6
Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
7
The Queen Elizabeth Hospital, Department of Surgery, University of Adelaide, Adelaide, South Australia, Australia.
8
Department of Surgery, Monash University, Melbourne, Victoria, Australia.
PMID:
33200521
DOI:
10.1111/ans.16214
No abstract available
MeSH terms
Bacteriophages*
Hernia
Herniorrhaphy
Humans
Phage Therapy*
Prostheses and Implants
Surgical Mesh
Surgical Wound Infection